ACCEL Lite: ESC Late Breaker: FIGARO-DKD: Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

<p>This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care, which includes glucose-lowering therapies, and maximum-tolerated, labelled doses of either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker.</p> <p>In this interview, Bertram Pitt, MD and Michelle L. O’Donoghue MD, FACC, with Michael Mikolaj MD, MPH, FACC, discuss ESC Late Breaker: FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes.</p> <p>Like what you hear? Get 20 episodes/month with CME/MOC credit! <a href="http://www.acc.org/ACCEL">www.acc.org/ACCEL</a></p> <p><a href= "https://itunes.apple.com/us/podcast/eagles-eye-view-your-weekly-cv-update-from-acc-org/id1274635046"> Subscribe on Apple</a> Podcasts | <a href= "https://play.google.com/music/listen#/ps/I6dtkumvaipematzgzmbph2koiq"> Subscribe on Google Play</a> | <a href= "http://www.acc.org/education-and-meetings/products-and-resources/accel-audio"> Subscribe to ACCEL</a></p>